Early ASCO winners? Roche and Pfizer, and to a lesser extent, BMS

The curtain is up on the first act of the annual cancer drug lollapalooza at ASCO. The first round of abstracts spotlights a series of early winners--including Roche ($RHHBY)--and at least one big loser: Puma Biotechnology ($PBYI). Bristol-Myers Squibb ($BMY) delivered some mixed results, while Pfizer ($PFE) was able to tout early data on a lung cancer treatment for patients who've failed on its targeted med Xalkori. More from FierceBiotech

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.